Verastem (VSTM) Cash & Current Investments (2011 - 2026)
Verastem's (VSTM) quarterly Cash & Current Investments came in at $197.8 million in Q1 2026, up 68.26% year-on-year from $117.6 million in Q1 2025, and down 3.49% quarter-over-quarter from $205.0 million in Q4 2025.
Verastem (VSTM) Cash & Current Investments (2011 - 2026) Analysis & Trends
Verastem's Cash & Current Investments history runs 16 years deep, the most recent figure standing at $197.8 million for Q1 2026.
- On a quarterly basis, Cash & Current Investments rose 68.26% year-over-year to $197.8 million in Q1 2026; TTM through Mar 2026 was $197.8 million, a 68.26% increase from a year earlier, with the FY2025 full-year figure at $205.0 million, up 130.8% from the prior year.
- Cash & Current Investments declined to $197.8 million in Q1 2026 per VSTM's latest filing, from $205.0 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $205.0 million in Q4 2025 and bottomed at $83.4 million in Q2 2024.
- The 5-year median for Cash & Current Investments is $113.2 million (2024), against an average of $130.1 million.
- Across the five-year window, Cash & Current Investments slumped 54.46% in 2024 and jumped 130.8% in 2025, its largest moves.
- Year by year, Cash & Current Investments stood at $92.0 million in 2022, then soared by 48.99% to $137.1 million in 2023, then plunged by 35.23% to $88.8 million in 2024, then soared by 130.8% to $205.0 million in 2025, then fell by 3.49% to $197.8 million in 2026.
- Per Business Quant, the three latest VSTM Cash & Current Investments figures stand at $197.8 million (Q1 2026), $205.0 million (Q4 2025), and $137.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Verastem | 627.10 Mn | 429.28 Mn | 15.90 Mn | 197.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 197.83 Mn |
| Dec 31, 2025 | 204.99 Mn |
| Sep 30, 2025 | 137.71 Mn |
| Jun 30, 2025 | 164.32 Mn |
| Mar 31, 2025 | 117.57 Mn |
| Dec 31, 2024 | 88.82 Mn |
| Sep 30, 2024 | 113.18 Mn |
| Jun 30, 2024 | 83.37 Mn |
| Mar 31, 2024 | 110.13 Mn |
| Dec 31, 2023 | 137.13 Mn |
| Sep 30, 2023 | 165.66 Mn |
| Jun 30, 2023 | 183.09 Mn |
| Mar 31, 2023 | 111.20 Mn |
| Dec 31, 2022 | 92.04 Mn |
| Sep 30, 2022 | 103.98 Mn |
| Jun 30, 2022 | 94.31 Mn |
| Mar 31, 2022 | 106.28 Mn |
| Dec 31, 2021 | 153.80 Mn |
| Sep 30, 2021 | 103.42 Mn |
| Jun 30, 2021 | 108.14 Mn |